BMS expects 9-13% decline in EPS after Plavix genericisation
05 March 2010
Simon Varcoe
Bristol-Myers Squibb expects its minimum projected non-GAAP EPS to be at least
9% lower in 2013 than its projected 2010 figure, as the loss of patent
exclusivity to its lead product, the blood thinner Plavix (clopidogrel),
takes full effect.
The company expects 2013 EPS to be at least...
Please Login to read the full article.
05 March 2010
Simon Varcoe
The company expects 2013 EPS to be at least...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
